Advertisement
Advertisement
Pfizer
TOPIC
 / company

Pfizer

Pfizer
Pfizer
The latest news, analysis and opinion on Pfizer. In-depth analysis, industry insights and expert opinion.
Chairman / President
Albert Bourla
CEO / Managing Director
Albert Bourla
CFO / Finance Director
Dave Denton
Industry
Pharmaceuticals
Website
pfizer.com
Headquarters address
235 East 42nd Street, New York, NY 10017, United States
Stock Code
NYSE:PFE
Year founded
1849
LATEST China Science NEWS

China’s J-36 fighter jet designers report danger of military AI hallucinations

videocam
20
China’s next-generation stealth fighter is unofficially known as the Chengdu J-36. Photo: X / Rupprecht_A

China joins Musk’s SpaceX with reusable rocket breakthroughs

LandSpace’s Zhuque-3 rocket takes off. Photo: CNS Photo via Reuters

Chinese coastguard proposes turning South China Sea isles into robotic fortress

videocam
5
Underwater drones, along with their aerial and surface counterparts, could be used to transform defences in the South China Sea. Photo: Reuters

China becomes first to recover orbital launch rockets with 2 distinct paths

videocam
53
In a global first, leading Chinese commercial rocket company LandSpace has recovered a stainless-steel booster after an orbital launch, marking a major step in the country’s efforts to develop lower-cost, reusable rockets. Photo: CCTV

Chinese doctors get double-thigh amputee to walk again in world first

The double-thigh replantation is a global first, according to the Jiangsu Trauma and Treatment Association – a local hospital network. Photo: Shutterstock
MORE China Science NEWS
Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, surpassed analysts’ expectations in the first half of the year. Photo: Handout
Banking & finance

China biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny

Strong orders for weight-loss and diabetes treatments drive firm’s growth, despite being caught up in US efforts to curb China’s ambitions.

China’s private sector

What would 200% US tariffs on generic drugs mean for China’s pharmaceutical industry?

videocam
16
United States

New York City races to secure unstable skyscraper after columns buckle, floors sag

China’s private sector

Bigger, fewer, tougher: the new era of China-US biotech partnerships

China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.

In focus: Chinese biotech firms such as Jiangsu Hengrui Pharmaceutical are navigating growing geopolitical scrutiny as cross-border licensing deals continue to expand. Photo: Shutterstoc
China’s private sector

Which company could become the Chinese Pfizer? Here are analysts’ top picks

A boom in outlicensing agreements leads to a debate over which Chinese firms may be first to break into overseas markets with own brands.

Biomedicine: Companies

China’s Innovent Biologics signs US$10.5b Pfizer deal for 12 cancer drug trials

The agreement covers eight early-stage trials from Innovent and four discovery programmes from global giant Pfizer.

videocam
Advertisement
Advertisement
Advertisement
Hong Kong economy

Which global firms are being attracted by Hong Kong’s strategic enterprise scheme?

The South China Morning Post examines 22 firms opening or expanding in the city, with HK$73 billion in investment and 25,000 jobs expected.

Pfizer, a leading global research‑based pharmaceutical and biotechnology company, is among the biggest names in the latest cohort. Photo: Reuters
Hong Kong economy

Pfizer, Amgen among 22 majors spreading wings in Hong Kong under investment push

Sixth batch under OASES initiative also features Boehringer Ingelheim, Hengrui and Haya, with Didi and AutoFlight joining transport push.

China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

Medicine

‘Save a fortune’: Trump unveils TrumpRx discount drug site

New platform connects American patients directly to drug makers with promised price cuts on popular medications like Ozempic.

US President Donald Trump at the TrumpRx website launch. Photo: EPA
Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

AI will allow drug makers to pick better molecules, make better medicines and improve molecule design, Amgen executive says. Photo: Shutterstock
Biomedicine: Industry Trends

Harbour BioMed stake in US drug developer shows Chinese firms’ growing clout

Latest example of Chinese drug maker acquiring equity in overseas partner shows they are becoming true development partners, analysts say.

Made in China 2025

Chinese biotechs strike a record US$136 billion in out-licensing deals in 2025

Chinese drug makers signed 157 out-licensing deals with global pharmaceutical firms last year versus 94 a year earlier.

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

The total pet population in China reached 430 million in 2024, with nearly one-third of urban cats classified as obese, according to the China Pet Industry Association. Photo: Shutterstock
United States

Are Chinese biotechs what the doctor ordered as Big Pharma faces ‘patent cliff’?

US drug makers are racing to plug looming ‘patent cliff’ revenue gaps – and increasingly they are turning to China biotechs.

US drugmakers are increasingly looking to Chinese biotechs as an answer to the revenue gaps left by the looming ‘patent cliff’. Illustration by Henry Wong
Made in China 2025

Chinese biotech Scizeng’s global licensing deal to yield up to US$1.44 billion

Yarrow Bioscience gets exclusive global rights for the GenSci098 therapy to treat thyroid eye disease and Graves’ disease.

Made in China 2025

China’s Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer

Yao Pharma’s deal with the US pharmaceutical giant underscores China’s growing role in global biotech licensing.

Advertisement
Advertisement
Advertisement
China economy

Opinion | How China engineered the rapid rise of its drug innovation industry

A market once dominated by generics is now an AI-powered pharmaceutical hub drawing billion-dollar investments from the likes of Pfizer and GSK.

videocam
A worker checks the position of a feeding tray in a pharmaceutical manufacturing facility at the Hengrui Biomedical Industrial Park in Lianyungang in Jiangsu province, on December 13, 2021. Photo: Getty Images
Science

Have Chinese chemists cracked the code for cheaper medicine production?

The research team’s straightforward alternative to expensive, complex and dangerous production method hailed as ‘Nobel Prize level’.

videocam
18
US-China relations

Xi-Trump summit opens window of opportunity for US firms at China import expo

More US companies are expected at this year’s China International Import Expo, hoping to secure deals in wake of bilateral summit.

videocam
Hong Kong economy

Letters | How Hong Kong can help Chinese drug makers go global

Readers discuss opportunities from medical innovation, tech standards in Hong Kong, and how to stop people treating corals like inanimate objects.

A view of the Hetao Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone on April 24. Photo: Edmond So
Donald Trump

Trump says Pfizer will cut drug prices for tariff relief

The White House is also planning a direct-to-consumer website called TrumpRx for Americans to buy medication.

The Pfizer logo is pictured at company headquarters in Berlin in January 2021. Photo: dpa
Singapore

Singapore’s drug makers may be shielded from US tariffs: Deputy PM Gan

The city state may pursue a ceiling on tariff rates similar to deals that Washington has with other countries, Deputy PM Gan Kim Yong adds.

Biomedicine: Companies

Pfizer’s Metsera acquisition to spur Chinese search for new weight drugs

The deal, worth up to US$7.3 billion, will encourage ongoing investment by mainland players but not draw in new rivals, analysts say.

Biomedicine: Companies

China’s Jiangsu Hengrui signs licensing deal with Braveheart Bio for heart drug

The licensing deal for the HRS-1893 innovative drug could fetch as much as US$1.01 billion in milestone payments.

The headquarters of Jiangsu Hengrui Pharmaceutical in Lianyungang Economic and Technological Development Zone, in Jiangsu province. Photo: Costfoto/Future Publishing via Getty Images
Made in China 2025

China vows stronger biotech support as deals with global drug makers surge

Chinese developers signed one-third of all agreements with global drug firms in the first half of 2025.

Scientist using microscope for chemistry test samples. Photo: Shutterstock
Biomedicine: Companies

Pfizer, Chinese biotech firm 3SBio complete licensing deal for cancer drug

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity investment in 3SBio.

European Union

EU chief Ursula von der Leyen easily survives parliament no-confidence vote

EU lawmakers dismissed allegations against Ursula von der Leyen regarding private text messaging with Pfizer’s CEO, misuse of funds, and election interference.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement